778
Views
20
CrossRef citations to date
0
Altmetric
Dermatology

Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States

ORCID Icon, &
Pages 735-742 | Received 21 Jan 2021, Accepted 18 Feb 2021, Published online: 25 Mar 2021

References

  • Kalb RE. Pustular psoriasis: pathogenesis, clinical manifestations, and diagnosis. UptoDate.com. 2019. https://www.uptodate.com/contents/pustular-psoriasis-pathogenesis-clinical-manifestations-and-diagnosis.
  • Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983–994..
  • Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis. 2016;6:131–144.
  • Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–684.
  • Borges-Costa J, Silva R, Goncalves L, et al. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271–276.
  • Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: a randomized, double-blind, placebo-controlled trial. J Dermatol. 2016;43(3):288–293.
  • Misiak-Galazka M, Wolska H, Rudnicka L, et al. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2017;31(1):38–44.
  • Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74(3):187–192.
  • Augey F, Renaudier P, Nicolas JP. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669–673.
  • Fabbri P. Psoriasis. From clinical diagnosis to new therapies. Florence (Italy): SEE-Firenze; 2004.
  • Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76:68–71.
  • Lee J, Kang YS, Park JS, et al. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance Database. Ann Dermatol. 2017;29(6):761–767.
  • Anderson YMF, Augustin M, Petersen J, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Derm. 2019;181(5):976–982.
  • Kharawala S, Golembesky AK, Bohn RL, et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Exp Rev Clin Immunol. 2020;16(3):239–252.
  • Kharawala S, Golembesky AK, Bohn RL, et al. The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review. Exp Rev Clin Immunol. 2020;16(3):253–266.
  • Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–288.
  • Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017.
  • Sano S, Kubo H, Morishima H, et al. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919.
  • Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of Guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154(3):309–316.
  • Wang W-M, Jin H-Z. Biologics in the treatment of pustular psoriasis. Exp Opin Drug Saf. 2020;19(8):910–969.
  • Trattner H, Blüml S, Steiner I, et al. Quality of life and comorbidities in palmoplantar pustulosis – a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol. 2017;31(10):1681–1685.
  • Kotowsky N, Gao R, Singer D, et al. PRO29 healthcare resource utilization (HCRU) in patients with generalized pustular psoriasis (GPP): a claims database study. Value Health. 23(S1):S333.
  • Kotowsky N, Gao R, Singer D, et al. PRO34 healthcare resource utilization (HCRU) in patients with palmoplantar pustulosis (PPP): a claims database study. Value Health. 23(S1):S335.
  • Miyazaki C, Sruamsiri R, Mahlich J, et al. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: a claims database study. PLoS One. 2020;15(5):e0232738.
  • Bureau of Labor Statistics (BLS). Measuring price change in the CPI: medical care. [cited 2020 Dec 2]. https://www.bls.gov/cpi/factsheets/medical-care.htm.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.